Ascendia

  MARKET NEWS

Mabion reactivates MabionCD20 through rare disease collaboration with Oddifact
LabGenius Therapeutics and LG Chem Enter a Research Collaboration, Option and License Agreement to Develop an AI/ML-Designed Tumour-Targeting Antibody
Alcami Expands Quality, Packaging, and Storage Capabilities at Tennessee Facility
InnoGI Technologies Launches TIM Cell to Bridge the Gap Between Bioaccessibility and Absorption

  FEATURED EDITORIAL

  EXPERT INSIGHTS VIDEOS

Enhancing Drug Bioavailability: Solubility Techniques and Innovations

Enhancing Drug Bioavailability: Solubility Techniques and Innovations

  COMPANY PROFILE

With over 75 years of proven experience, Aptar Pharma is the go-to drug delivery expert, for pharma customers worldwide, from formulation to patient, providing innovative drug delivery systems, components and active material solutions across the widest range of delivery routes, including nasal, pulmonary, ophthalmic, dermal and injectables. Aptar Pharma Services provides early-stage to commercialization support to accelerate and derisk the development journey. With a strong focus on innovation, Aptar Digital Health is a leading provider of integrated digital health solutions to enhance patient experiences across their treatment journey. With a global manufacturing footprint of 14 manufacturing sites, Aptar Pharma provides security of supply and local support to customers. Aptar Pharma is part of AptarGroup, Inc.

Click here for more.

  WHITEPAPERS & WEBINARS

WEBINAR ON DEMAND: Why early matters: Data-driven strategies to de-risk OSD development

WEBINAR ON DEMAND: Why early matters: Data-driven strategies to de-risk OSD development

Late-stage surprises continue to drive cost, delay, and challenges in oral solid dosage (OSD) development—especially for complex, poorly soluble molecules. Too often, formulation and manufacturability risks surface only after significant time and investment.

In a recent panel discussion, GlobalData’s Director …

WHITEPAPER - An Introduction to PLG Polymers for Long‑Acting Drug Delivery

WHITEPAPER - An Introduction to PLG Polymers for Long‑Acting Drug Delivery

Bioabsorbable poly(lactide-co‑glycolide) (PLG) polymers and poly(lactic acid-co-glycolic acid) (PLGA) have become an essential part of modern healthcare. Over the past five decades, these polymers have transformed how medicines are delivered – enabling long-acting injectables, implants, and localized drug‑delivery products …

WHITEPAPER - From Service Provider to Strategic Partner

WHITEPAPER - From Service Provider to Strategic Partner

By: Tom Sellig, CEO, Adare Pharma Solutions

As drug development grows more complex and timelines compress, sponsors require CDMO relationships built on integration, flexibility, and shared accountability. The relationship between pharmaceutical sponsors and their CDMO partners has undergone a fundamental …

WHITEPAPER - Stop Guessing. Start Predicting: Rethinking Early Oral Drug Development

WHITEPAPER - Stop Guessing. Start Predicting: Rethinking Early Oral Drug Development

Why Early Development Requires a Different Decision Model

Early oral drug development is an exercise in working under constraint. Teams are asked to make consequential decisions when materials are limited, timelines are tight, and the data are incomplete. Traditionally, formulation …

WHITEPAPER - Small Molecules: Choosing the Right Development Path

WHITEPAPER - Small Molecules: Choosing the Right Development Path

Summary

The white paper, Small Molecules: Choosing the Right Development Path, outlines a structured, risk-minimized approach to early CMC (Chemistry, Manufacturing, and Controls) development for small-molecule drugs—particularly for startups and virtual pharma companies with limited resources.

Key messages:

  • Start
…

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

July 1 – Prefilled Syringes
July 8 – Analytical Testing
July 15 – ODT/Fast Dissolve
July 22 – Transdermal/Topical